Sid P. Kerkar

490 BioTech (United States) — United States

Medicine · Health Sciences

24h-index6.6kcitations121works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(77), Immunotherapy and Immune Responses(48), Cancer Immunotherapy and Biomarkers(36), Virus-based gene therapy research(26), Immune Cell Function and Interaction(24)

Publications121 total

Abstract 4016: mRNA encoding a CAR specific stimulating protein (CSSP) mediates tumor metabolism regulated (TMR) CAR signaling for CAR-T expansion beyond the tumor microenvironment
Cancer Research·2024
Development of a Same-Day Closed CAR-T Cell Manufacturing Process to Generate Lentivector Loaded Lymphocytes Ready for Subcutaneous Injection
Blood·2023· 1 citedOpen Access
Abstract 2918: <i>In vivo</i> delivery of CD3-directed CD19-CAR lentivectors leads to the generation of CAR T and NK-like (CAR-TaNK) cells capable of complete ablation of B cells in the blood, bone marrow, and tissue of NSG-SGM3 CD34+ humanized mice
Cancer Research·2023· 1 cited
Supplemental figure 4 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplemental Information from Targeting of HPV-16&lt;sup&gt;+&lt;/sup&gt; Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
2023Open Access
Supplemental figure 4 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplemental figure 5 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplementary Figure 1 from Determinants of Successful CD8&lt;sup&gt;+&lt;/sup&gt; T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
2023Open Access
Data from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplemental figure 1 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplementary Materials and Methods from Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
2023Open Access
Data from Determinants of Successful CD8&lt;sup&gt;+&lt;/sup&gt; T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
2023Open Access
Supplemental figure 2 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Data from Determinants of Successful CD8&lt;sup&gt;+&lt;/sup&gt; T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
2023Open Access
Supplemental figure 3 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplementary Materials and Methods from Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
2023Open Access
Supplemental Information from Targeting of HPV-16&lt;sup&gt;+&lt;/sup&gt; Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
2023Open Access
Data from Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
2023Open Access
Supplemental figure 5 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplementary Figure 2 from Determinants of Successful CD8&lt;sup&gt;+&lt;/sup&gt; T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Nicholas P. Restifo(22), Steven A. Rosenberg(21), Pawel Muranski(13), Zhiya Yu(12), Luca Gattinoni(11), Douglas C. Palmer(10), Zachary A. Borman(9), Christopher A. Klebanoff(7), Luis Sánchez-Pérez(7), Christian S. Hinrichs(7), Richard A. Morgan(6), Christopher P. Steffes(6), James G. Tyburski(6), Robert Reger(5), Richard A. Morgan(5), Ling Zhang(5), Yun Ji(4), Rahul Roychoudhuri(4), Mark E. Dudley(4), Richard M. Sherry(4)